default author photo

Silke Buda

Robert Koch Institute

Berlin

Germany

SCHOLARLY PAPERS

2

DOWNLOADS

215

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network

Number of pages: 20 Posted: 21 Mar 2025
Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Carlos III Institute of Health - Communicable Diseases Department, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Epiconcept, Subdirección General de Epidemiología y Vigilancia de la Salud, Health Service Executive, University of Paris-Saclay - Institut Pasteur, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Murcia Regional Health Council-IMIB, University College Dublin (UCD), University of Corsica, Robert Koch Institute - Department for Infectious Disease Epidemiology, NIVEL (Netherlands Institute for Health Services Research), Croatian Institute of Public Health, Semmelweis University, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Cantacuzino National Military Medical Institute for Research and Development, Public Health Agency of Sweden, National Health Institute Doutor Ricardo Jorge (INSA) - Bioinformatics Unit, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 109 (649,907)

Abstract:

Loading...

COVID-19, vaccine effectiveness, SARS-CoV-2, Europe

2.

Effectiveness of XBB.1.5 Vaccines against Symptomatic SARS-CoV-2 Infection in Older Adults during the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024

Number of pages: 17 Posted: 11 Jul 2024
Epiconcept - Epidemiology Department, Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Carlos III Institute of Health, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Robert Koch Institute, NIVEL (Netherlands Institute for Health Services Research), National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Semmelweis University, Public Health Agency of Sweden, Croatian Institute of Public Health, Cantacuzino National Military Medical Institute for Research and Development, Epiconcept, Consejería de Sanidad - Dirección General de Salud Pública, University College Dublin (UCD), University of Paris-Saclay - Laboratoire de Microbiologie, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, National Institute of Health Doutor Ricardo Jorge, Semmelweis University, Public Health Agency of Sweden, Croatian Institute of Public Health, National Institute for Public Health and the Environment (RIVM), National Institute of Health Doutor Ricardo Jorge, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 106 (664,543)

Abstract:

Loading...

COVID-19, SARS-CoV-2, Vaccine effectiveness, Primary care, Case-control study, Test-negative design, Multi-country study